MGX
Metagenomi, Inc. Common Stock NASDAQ Listed Apr 6, 2006$1.20
+1.69%
vs $1.18
Mkt Cap $44.7M
52w Low $1.14
2.7% of range
52w High $3.35
50d MA $1.35
200d MA $1.74
P/E (TTM)
-0.5x
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.3x
ROE
-55.4%
P/FCF
-0.5x
RSI (14)
28.90
ATR (14)
$0.06
Beta
0.57
50d MA
$1.35
200d MA
$1.74
Avg Volume
184.4K
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
CIK (SEC)
Phone
510-871-4880
5959 Horton Street · Emeryville 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.58 | -0.60 | -3.4% | 1.61 | -3.7% | -8.1% | +8.1% | +10.0% | -6.8% | -4.3% | — |
| Nov 11, 2025 | AMC | -0.60 | -0.55 | +8.3% | 2.20 | -9.1% | -15.5% | -8.6% | +2.4% | -2.3% | +0.0% | — |
| Aug 12, 2025 | AMC | -0.68 | -0.54 | +20.6% | 1.88 | +2.1% | +3.2% | -2.1% | -2.1% | +3.2% | -4.7% | — |
| May 13, 2025 | AMC | -0.62 | -0.68 | -9.7% | 1.60 | +0.6% | -6.2% | +4.0% | +6.4% | +3.0% | -0.6% | — |
| Mar 17, 2025 | AMC | -0.62 | -0.63 | -1.6% | 1.88 | -1.6% | -8.0% | -1.2% | -1.8% | -2.4% | +0.6% | — |
| Nov 13, 2024 | AMC | -0.70 | -0.45 | +35.7% | 2.11 | +9.0% | -10.9% | -3.2% | -3.8% | -3.4% | -2.4% | — |
| Aug 14, 2024 | AMC | -0.59 | -0.29 | +50.8% | 3.10 | -2.6% | -5.5% | -3.8% | +11.7% | +4.8% | +0.6% | — |
| May 14, 2024 | AMC | -0.95 | -1.19 | -25.3% | 6.54 | -0.6% | +4.0% | +2.9% | +0.0% | -4.4% | +6.1% | — |
| Feb 10, 2024 | AMC | -2.04 | -0.51 | +74.8% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.53 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.35 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.54 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $1.94 | +1.0% | -4.7% | +1.1% | +0.0% | +4.3% | -2.6% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.90 | $1.84 | -3.2% | -2.1% | +3.2% | -4.7% | +1.1% | +0.0% |
| Aug 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.94 | $1.95 | +0.5% | -2.1% | -2.1% | +3.2% | -4.7% | +1.1% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.50 | $1.50 | +0.0% | +4.0% | +6.4% | +3.0% | -0.6% | -2.9% |
| May 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.60 | $1.61 | +0.6% | -6.2% | +4.0% | +6.4% | +3.0% | -0.6% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.33 | +0.0% | -5.3% | +11.9% | +1.4% | -2.1% | +7.1% |
| Mar 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.88 | $1.85 | -1.6% | -8.0% | -1.2% | -1.8% | -2.4% | +0.6% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.17 | $4.22 | +1.2% | +0.5% | -5.7% | -2.3% | -16.1% | -4.0% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.67 | +1.2% | +10.3% | +3.8% | +6.3% | +0.0% | +0.5% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $1.69 | $1.70 | +0.6% | -2.4% | +10.3% | +3.8% | +6.3% | +0.0% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.93 | -1.0% | +1.0% | +1.0% | +0.0% | -1.5% | -2.0% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $2.84 | -2.1% | -6.2% | +6.6% | -5.2% | +1.1% | -3.2% |
| Sep 5 | Chardan Capital | Maintains | Buy → Buy | — | $2.80 | $2.80 | +0.0% | +3.6% | -6.2% | +6.6% | -5.2% | +1.1% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.30 | $3.30 | +0.0% | +0.6% | -7.8% | +5.2% | +0.9% | -2.5% |
| Aug 19 | Chardan Capital | Maintains | Buy → Buy | — | $2.82 | $2.80 | -0.7% | +11.7% | +4.8% | +0.6% | -7.8% | +5.2% |
| Aug 15 | BMO Capital | Maintains | Outperform → Outperform | — | $3.10 | $3.02 | -2.6% | -5.5% | -3.8% | +11.7% | +4.8% | +0.6% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.14 | $5.22 | +1.6% | -4.1% | +6.5% | -1.3% | -7.9% | -0.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.50 | -0.6% | +4.0% | +2.9% | +0.0% | -4.4% | +6.1% |
| May 2 | JP Morgan | Downgrade | Overweight → Neutral | — | $7.04 | $6.34 | -9.9% | -12.4% | +2.4% | +2.4% | -0.2% | +5.3% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $11.09 | $11.00 | -0.8% | -4.9% | +2.6% | -5.2% | +2.2% | -3.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Wein Matthew | See Remarks | Sell | 558 | $1.30 | $725 | 126,491 | +1.63% | +3.51% |
| Jun 5, 2026 | Irish Jian | See Remarks | Sell | 3,737 | $1.30 | $5K | 377,533 | +1.63% | +3.51% |
| Jun 5, 2026 | Wapnick Pamela | Chief Financial Officer | Sell | 2,884 | $1.30 | $4K | 208,491 | +1.63% | +3.51% |
8-K · 5.02
!!! Very High
Metagenomi, Inc. -- 8-K 5.02: Executive Change
Jun 10
8-K
Metagenomi Therapeutics, Inc. -- 8-K Filing
Metagenomi Therapeutics holds $160.8 million in cash with runway extending through Q4 2027, providing investors confidence in the biotech firm's ability to fund operations and advance its genome editing pipeline.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,057,944 | $1M | New | Mar 2026 |
| 2 | Renaissance Technologies Llc | 787,900 | $1M | Added | Mar 2026 |
| 3 | Jane Street Group, Llc | 433,859 | $703K | Added | Dec 2025 |
| 4 | Peapod Lane Capital Llc | 516,761 | $683K | Added | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 496,767 | $666K | Added | Mar 2026 |
| 6 | Wells Fargo & Company/mn | 202,138 | $271K | New | Mar 2026 |
| 7 | Millennium Management | 170,104 | $228K | Reduced | Mar 2026 |
| 8 | Morgan Stanley | 119,364 | $193K | Reduced | Dec 2025 |
| 9 | Rbf Capital, Llc | 128,042 | $172K | — | Mar 2026 |
| 10 | Man Group Plc | 78,636 | $105K | Added | Mar 2026 |
| 11 | Northern Trust Corp | 75,172 | $101K | — | Mar 2026 |
| 12 | Marshall Wace, Llp | 27,521 | $37K | Reduced | Mar 2026 |
| 13 | Citadel Advisors Llc | 16,993 | $23K | Reduced | Mar 2026 |
| 14 | Ubs Group Ag | 16,098 | $22K | Reduced | Mar 2026 |
| 15 | Peak Planning Group, Llc | 12,500 | $17K | — | Mar 2026 |
| 16 | Point72 Asset Management | 11,726 | $16K | Reduced | Mar 2026 |
| 17 | Hrt Financial Lp | 10,674 | $14K | Reduced | Mar 2026 |
| 18 | Us Bancorp \de\ | 4,500 | $7K | — | Dec 2025 |
| 19 | Fmr Llc | 4,718 | $6K | Reduced | Mar 2026 |
| 20 | Russell Investments Group, Ltd. | 4,179 | $6K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Fund | 327,100 | $438K | Mar 2026 |
| 2 | Old Westbury Small & Mid Cap Strategies Fund | 737,603 | $252K | Jan 2026 |
| 3 | Fidelity Extended Market Index Fund | 151,691 | $231K | Feb 2026 |
| 4 | iShares Micro-Cap ETF | 70,127 | $94K | Mar 2026 |
| 5 | Ultra-Small Company Market Fund | 62,200 | $83K | Mar 2026 |
| 6 | Fidelity Total Market Index Fund | 47,211 | $72K | Feb 2026 |
| 7 | Avantis International Equity ETF | 191,102 | $65K | Feb 2026 |
| 8 | Fidelity Series Total Market Index Fund | 36,088 | $55K | Feb 2026 |
| 9 | Fidelity Nasdaq Composite Index Fund | 21,951 | $33K | Feb 2026 |
| 10 | Avantis International Small Cap Value Fund | 54,215 | $18K | Feb 2026 |
| 11 | Spectrum Fund | 5,496 | $7K | Mar 2026 |
| 12 | Avantis International Small Cap Equity ETF | 19,742 | $7K | Feb 2026 |
| 13 | Avantis U.S. Small Cap Equity ETF | 3,454 | $5K | Feb 2026 |
| 14 | Avantis International Equity Fund | 15,532 | $5K | Feb 2026 |
Valuation
Market Cap
$44.7M
Enterprise Value
-$116.1M
P/E (TTM)
-0.51x
Forward P/E
—
PEG Ratio
-0.05x
P/B
0.28x
P/S
1.77x
P/FCF
-0.50x
EV/EBITDA
—
Shares Out
37.3M
Financials (TTM)
Revenue
$25.2M
Net Income
-$87.9M
EBITDA
-$90.7M
Free Cash Flow
-$89.5M
Op Cash Flow
-$88.9M
EPS Basic
$-2.36
EPS Diluted
$-2.36
EPS Forward
$-2.12
Gross Margin
78.9%
Op Margin
-380.9%
Net Margin
-348.5%
Balance Sheet
Total Assets
$221.1M
Total Liab.
$62.5M
Total Equity
$158.6M
Cash
$160.8M
LT Debt
$0
Book Value/Sh
$4.26
Debt/Equity
0.26x
Current Ratio
7.22
Quick Ratio
7.22
Returns & Growth
ROE
-55.4%
ROA
-39.7%
ROIC
-47.0%
Rev Growth YoY
-51.8%
EPS Growth YoY
-12.9%
Price Returns
2W
+0.7%
1M
-1.4%
3M
-10.5%
6M
-22.3%
12M
-20.0%
Technicals
52W High
$3.35
52W Low
$1.14
50d MA
$1.35
200d MA
$1.74
RSI (14)
28.90
ATR (14)
$0.06
Beta
0.57
Avg Volume
184K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$14.50
High
$22.00
Low
$7.00
Median
$14.50
Data updated apr 26, 2026 12:11pm
· Source: financialmodelingprep.com